Solid lipid nanoparticles (SLNs, sLNPs), or lipid nanoparticles (LNPs), are nanoparticles composed of lipids. They are a novel pharmaceutical drug delivery system (and part of nanoparticle drug delivery), and a novel pharmaceutical formulation.[1][2] LNPs as a drug delivery vehicle were first approved in 2018 for the siRNA drug, Onpattro.[3] LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).[4] .
True, the brain is the body's command center, but the immune system—unlike our organs—is not in one place. Immune cells rove freely through the blood and into most of our tissues and can respond relatively independently to local conditions.
Antibodies attacking brain tissue can trigger neuropsychiatric symptoms. Certain infections can trigger an abnormal immune response, whereby antibodies mistakenly attack healthy cells in the brain which can result in basal ganglia encephalitis.
